In
this latest study, researchers noted significant
improvements
in ventilation function for a number of bronchiectasis patients after
three weeks of using the Aerobika® device. There were no adverse
events related to the use of the device reported during the study.1
Bronchiectasis
is a condition in which the structure and function of the airways
become permanently damaged, usually as the result of infection or
other condition. Patients suffering from chronic bronchiectasis
typically have trouble clearing mucus from airways and suffer from a
repeating pattern of airway damage, mucus buildup, and recurrent
infections. The result is typically a vicious cycle of decline,
resulting in reduced air exchange in the smaller airways.
There
are three primary goals in the successful treatment of
bronchiectasis:
1.
Treat any underlying conditions and lung infections
2.
Remove mucus from the lungs, and
3.
Prevent complications
"This
most recent study just adds to the mounting clinical evidence that
our Aerobika® device is effective for patients with bronchiectasis,
COPD, and related respiratory disease," said Dominic Coppolo,
MBA, RRT, FAARC, Vice President Clinical Strategy and Development at
Monaghan Medical. "We are always pleased to see real-world
findings that demonstrate the efficacy of our Aerobika® device in
clearing mucus to improve lung function in patients with chronic
bronchial ailments as well as high-risk COPD patients."
Overlap
between bronchiectasis and COPD
Researchers
have observed overlap between bronchiectasis and other chronic airway
diseases such as chronic obstructive pulmonary disease (COPD).
Studies show that these types of patients tend to have higher rates
of exacerbation and worse outcomes.1 The overlap between
bronchiectasis and COPD was highlighted in a recent study presented
at the 2016 CHEST annual meeting in October. Investigators found that
92.7 percent of COPD patients who had experienced more than one
exacerbation in the previous 12 months also had bronchiectasis.2
The
results of the study published in Academic Radiology showing
effectiveness in treating bronchiectasis patients using the Aerobika®
device are in line with another 2016 real-world study presented at
the European Respiratory Society (ERS) International Congress.
Investigators found the Aerobika® device demonstrated a clinically
significant reduction in exacerbations in as little as 30 days of
treatment when used as an add-on to usual COPD medications.3
About
the bronchiectasis Aerobika® device study
Fifteen
participants with non-CF bronchiectasis and 15 age-matched healthy
volunteers underwent spirometry, plethysmography, computed tomography
(CT), and hyperpolarized 3 He magnetic resonance imaging
(MRI). Bronchiectasis patients also completed a Six-Minute Walk Test,
the St. George's Respiratory questionnaire, and Patient Evaluation
Questionnaire (PEQ), and returned for a follow-up visit after three
weeks of daily oscillatory positive expiratory pressure (Aerobika®
device) use. Supplementary data related to this study can be found at
dx.doi.org/10.1016/j.acra.2016.08.021.
About
the bronchiectasis and COPD overlap study
A
retrospective study of the medical records of 961 stable COPD
outpatients who were followed regularly during the period 2011-2015
at least twice/year. Complete medical records were found in 855
patients who were eligible for the analysis. Results were presented
at the 2016 CHEST annual meeting.
The
complete study can be found at
http://journal.publications.chestnet.org/article.aspx?articleid=2568609
About
the Aerobika® device real-world COPD study
A
retrospective cohort study of the CDM hospital claims database was
conducted between September 2013 and August 2015. The final study
sample comprised of 810 patients; 405 received an Aerobika® device
and 405 were propensity score matched. The study inclusion criteria
were: ≥1 record pre-index, ≥1 record post-index, newly initiated
on the Aerobika® device, ≥1 diagnosis of CB on/before index, ≥18
years old, no evidence of other PEP/OPEP anytime, with complete
records. See more at:
http://erj.ersjournals.com/content/48/suppl_60/PA3780
About
the Aerobika® device
The
Aerobika® device is hand-held, easy-to-use and drug-free. When the
patient exhales through the device, intermittent resistance creates
positive pressure and oscillations simultaneously, which expands the
airways, helps expel the mucus to the upper airways where it can be
coughed out, and may also aid in improved drug deposition. The
Aerobika® device is available in Canada, Mexico, and select European
countries including the UK and Germany through Trudell Medical
International and in the US via Monaghan Medical Corporation.
(http://www.monaghanmed.com/Aerobika-OPEP)
About
Monaghan Medical Corporation (MMC, USA)
MMC
offers leading aerosol drug delivery devices and respiratory
management products including AeroEclipse® II BAN,
AeroChamber Plus® aVHC and the Aerobika®
device exclusively in the United States. MMC's strength lies in
product development around core capabilities in mechanical design
complimented by collaboration with a state-of-the-art aerosol
research laboratory. MMC focuses on developing cost-efficient,
outcome-based solutions for its customers.
(http://www.monaghanmed.com)
For
clinical inquiries, please contact:
Dominic
P. Coppolo, MBA, RRT, FAARC
Vice
President of Clinical Strategy and Development
Monaghan
Medical Corporation
1-800-343-9071
References:
[1]
Svenningsen S et al. Noncystic Fibrosis Bronchiectasis: Regional
Abnormalities and Response to Airway Clearance Therapy Using
Pulmonary Functional Magnetic Resonance Imaging. Acad Radiol. January
2017; 24:1,4-12.
[2]
Kosmas E, et al. Bronchiectasis in Patients With COPD: An Irrelevant
Imaging Finding or a Clinically Important Phenotype? Chest.
2016;150(4_S):894A.
[3]
Suggett J. A Retrospective Cohort Study Demonstrating the Impact of
an OPEP Device on Exacerbations in COPD Patients with Chronic
Bronchitis. Presented at ERS 2016. Eur Respir J. 2016;48:PA3780.
